Vizora日本語

Human Metabolome TechnologiesHuman Metabolome Technologies, Inc.6090東証スタンダードサービス業FY ending Jun 2026, consolidated, J-GAAP

Human Metabolome Technologies FY ending Jun 2022 results

About 100% of Human Metabolome Technologies's sales come from Researchsupport analysis, with healthcare analysis making up much of the rest.

Out of every ¥100 of sales, about ¥16 is left as operating profit.

Revenue changed +8.8% from the prior year, operating profit +385.5%.

Revenue and profit pattern

Revenue and profit upProfit grew faster

Revenue +8.8% · profit +385.5%, calculated from disclosed figures.

Operating leverage: 43.68× (profit growth ÷ revenue growth)

What changed from last year

FY ending Jun 2021 → FY ending Jun 2022

Revenue
+8.8%¥1.12B → ¥1.22B
Gross profit
+4.2%¥806M → ¥840M
Operating income
+385.5%¥39.4M → ¥191.2M
Net income attributable to owners
+360.0%¥58.2M → ¥267.8M
Operating cash flow
Back to profit-¥34.2M → ¥324M
Free cash flow
Back to profit-¥62M → ¥177.9M

Where the money goes

FY ending Jun 2021 → FY ending Jun 2022

Where ¥100 of sales goes

For every ¥100 Human Metabolome Technologies sells, how much goes where, and how much is kept.

FY ending Jun 2022
Cost of sales
¥31
SG&A
¥53
Operating profit
¥16
Net profit kept
¥22

Annual margin trends

Gross margin68.7%
FY ending Jun 2020: 76.6%76.6%FY ending Jun 2021: 71.7%71.7%FY ending Jun 2022: 68.7%68.7%FY20FY21FY22
Operating margin15.6%
FY ending Jun 2020: -1.5%-1.5%FY ending Jun 2021: 3.5%3.5%FY ending Jun 2022: 15.6%15.6%FY20FY21FY22
Net margin21.9%
FY ending Jun 2020: -4.3%-4.3%FY ending Jun 2021: 5.2%5.2%FY ending Jun 2022: 21.9%21.9%FY20FY21FY22

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Jun 2022
  • Researchsupport analysis¥1.22B
    100%
    Op. margin 27.2%
  • healthcare analysis¥2.9M
    0%
    Op. margin -4931.4%

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (6)

  • EDINET (FSA Japan)

    有価証券報告書－第23期(2025/07/01－2026/06/30)

    ID S100Z2EI2026-09-17Open

  • EDINET (FSA Japan)

    有価証券報告書－第22期(2024/07/01－2025/06/30)

    ID S100WPSX2025-09-22Open

  • EDINET (FSA Japan)

    有価証券報告書－第21期(2023/07/01－2024/06/30)

    ID S100UE9D2024-09-24Open

  • EDINET (FSA Japan)

    有価証券報告書－第20期(2022/07/01－2023/06/30)

    ID S100RW1Z2023-09-25Open

  • EDINET (FSA Japan)

    有価証券報告書－第19期(令和3年7月1日－令和4年6月30日)

    ID S100P8152022-09-26Open

  • EDINET (FSA Japan)

    有価証券報告書－第18期(令和2年7月1日－令和3年6月30日)

    ID S100MHKD2021-09-27Open

Extracted from XBRL: 45 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image